Miniatura

Fitxers

526521.pdf (184.49 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2001-01-18

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/121968

A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1056/NEJM200101183440301

Resum

Background: Prophylaxis against Pneumocystis carinii pneumonia is indicated in patients with human immunodeficiency virus (HIV) infection who have less than 200 CD4 cells per cubic millimeter and in those with a history of P. carinii pneumonia. However, it is not clear whether prophylaxis can be safely discontinued after CD4 cell counts increase in response to highly active antiretroviral therapy. Methods: We conducted a randomized trial of the discontinuation of primary or secondary prophylaxis against P. carinii pneumonia in HIV-infected patients with a sustained response to antiretroviral therapy, defined by a CD4 cell count of 200 or more per cubic millimeter and a plasma HIV type 1 (HIV-1) RNA level of less than 5000 copies per milliliter for at least three months. Prophylactic treatment was restarted if the CD4 cell count declined to less than 200 per cubic millimeter. Results: The 474 patients receiving primary prophylaxis had a median CD4 cell count at entry of 342 per cubic millimeter, and 38 percent had detectable HIV-1 RNA. After a median follow-up period of 20 months (388 person-years), there had been no episodes of P. carinii pneumonia in the 240 patients who discontinued prophylaxis (95 percent confidence interval, 0 to 0.85 episode per 100 person-years). For the 113 patients receiving secondary prophylaxis, the median CD4 cell count at entry was 355 per cubic millimeter, and 24 percent had detectable HIV-1 RNA. After a median follow-up period of 12 months (65 person-years), there had been no episodes of P. carinii pneumonia in the 60 patients who discontinued prophylaxis (95 percent confidence interval, 0 to 4.57 episodes per 100 person-years). Conclusions: In HIV-infected patients receiving highly active antiretroviral therapy, primary and secondary prophylaxis against P. carinii pneumonia can be safely discontinued after the CD4 cell count has increased to 200 or more per cubic millimeter for more than three months.

Matèries

Infeccions per VIH, Persones seropositives, Antiretrovirals, Pneumònia

Matèries (anglès)

HIV infections, HIV-positive persons, Antiretroviral agents, Pneumonia

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Medicina)

Citació

LÓPEZ BERNALDO DE QUIRÓS, Juan carlos, MIRÓ MEDA, José m. (josé maría), PEÑA, Jose m., PODZAMCZER PALTER, Daniel, ALBERDI, Juan c., MARTÍNEZ CHAMORRO, Esteban josé, COSÍN, Jaime, CLARAMONTE, Xavier, GONZÁLEZ, Juan, DOMINGO, Pere (domingo pedrol), CASADO, Jose l., RIBERA, Esteban, Grupo de Estudio del SIDA 04/98, SANTÍN CEREZALES, Miguel. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. _New England Journal of Medicine_. 2001. Vol. 344, núm. 3, pàgs. 159-167. [consulta: 14 de gener de 2026]. ISSN: 0028-4793. [Disponible a: https://hdl.handle.net/2445/121968]

Exportar metadades

JSON - METS

Compartir registre